MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Up 29.4% in February

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) saw a significant increase in short interest in the month of February. As of February 13th, there was short interest totaling 568,283 shares, an increase of 29.4% from the January 29th total of 439,335 shares. Currently, 1.5% of the shares of the company are short sold. Based on an average daily volume of 136,480 shares, the days-to-cover ratio is currently 4.2 days. Based on an average daily volume of 136,480 shares, the days-to-cover ratio is currently 4.2 days. Currently, 1.5% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of MIRA Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 22nd. Rodman & Renshaw assumed coverage on MIRA Pharmaceuticals in a research note on Tuesday, January 13th. They set a “buy” rating for the company. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a research note on Monday, December 29th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold”.

MIRA Pharmaceuticals Price Performance

NASDAQ MIRA traded down $0.02 on Wednesday, hitting $1.22. 377,313 shares of the company’s stock were exchanged, compared to its average volume of 124,161. The firm’s 50-day moving average price is $1.34 and its two-hundred day moving average price is $1.40. MIRA Pharmaceuticals has a fifty-two week low of $0.73 and a fifty-two week high of $2.45. The firm has a market cap of $51.09 million, a price-to-earnings ratio of -0.80 and a beta of 1.78.

Institutional Investors Weigh In On MIRA Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in MIRA. XTX Topco Ltd acquired a new position in shares of MIRA Pharmaceuticals in the second quarter valued at approximately $26,000. Creative Planning purchased a new position in MIRA Pharmaceuticals in the second quarter valued at about $27,000. Fifth Third Bancorp acquired a new position in MIRA Pharmaceuticals during the 4th quarter worth approximately $30,000. Two Sigma Investments LP boosted its stake in shares of MIRA Pharmaceuticals by 129.8% in the third quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock valued at $62,000 after purchasing an additional 25,816 shares during the period. Finally, First American Bank grew its stake in shares of MIRA Pharmaceuticals by 150.0% during the third quarter. First American Bank now owns 50,000 shares of the company’s stock valued at $68,000 after acquiring an additional 30,000 shares in the last quarter. 35.16% of the stock is owned by institutional investors and hedge funds.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.